GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...

The company's revenue jumped 77% in Q3 to reach $401.6 million in Q3 2024, alongside a net income of $75.6 million. It now ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Options Medical Weight Loss, the nation's premier medical weight loss clinic, is proud to announce its inclusion on Newsweek's 2025 list of America's Best Weight Loss Clinics & Centers. Presented in ...

Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including World <a target=_blank ...

In a recent federal benefits survey, OPM found that 81% of respondents identified out-of-pocket costs as a top factor when selecting a health plan.